Head-to-head evidence
SHR6508 vs Upacicalcet
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Calcium-sensing receptor (CaSR) · full Chronic Kidney Disease pipeline
SHR6508
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06236295 · Phase 2 · completed
The study is a single-group, unblinded trial of 303 participants, with no placebo or active comparator. Its primary endpoint is the incidence and severity of adverse events, but results are not posted, so whether this endpoint was met cannot be determined.
Upacicalcet · UPASITA
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT05836220 · Phase 3 · completed
The study randomly assigned 412 participants to triple-blinded PLS240 or placebo, providing a well-controlled comparison. However, results for the primary iPTH reduction endpoint have not been posted, and this endpoint is a biochemical surrogate rather than a hard clinical or endoscopic outcome.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR6508's landscape · Upacicalcet's landscape